Company / PP&E per Share
Myriad Genetics, Inc. PP&E per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$1.40
FY2025
5-year range
$0.62 / $1.58
FY2021-FY2025
Trend
-4.3%
vs FY2024
Sector context
#38 of 191
Health Care
What the data says
Myriad Genetics, Inc.'s pp&e per share of $1.40 is higher than 80% of companies in the Health Care sector (FY2025). PP&E per Share has fluctuated over the past 10 years, ranging from $0.60 in FY2020 to $1.58 in FY2023.
Based on SEC 10-K filings.
1.40 in FY2025 with a 5-year CAGR of +18.7%. Top quartile in the Health Care sector.
Declined from $1.58 to $1.40 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- +7.4%
- 5-Year CAGR
- +18.7%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 191This company $1.40 Sector average $18.90
▼
-92.6% below sector average
Key checks
Key Insights
- In FY2025, pp&e per share decreased 4.3% year-over-year.
- Ranks #38 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2023.
- Lowest pp&e per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.40 | -4.3% |
| FY2024 | $1.47 | -7.0% |
| FY2023 | $1.58 | +39.1% |
| FY2022 | $1.13 | +84.2% |
| FY2021 | $0.62 | +3.5% |
| FY2020 | $0.60 | -28.2% |
| FY2019 | $0.83 | +32.3% |
| FY2018 | $0.63 | -9.8% |
| FY2017 | $0.70 | -3.9% |
| FY2016 | $0.72 | -11.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026